Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluoropyrimidine derivatives; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms STEAM
- Sponsors Roche
- 21 Sep 2020 Results of systemic review and meta analysis comparing efficacy FOLFOXIRI and doublets with targeted therapy in pts with mBRAF mCRC in terms of progression free survival, objective response rate and overall survival presented at the 45th European Society for Medical Oncology Congress
- 20 Aug 2020 Results (n=1697) of meta-analysis of 5 studies (CHARTA; NCT01321957, OLIVIA; NCT00778102, STEAM; NCT01765582, TRIBE; NCT00719797, and TRIBE2; NCT02339116) assessing survival, published in the Journal of Clinical Oncology.
- 31 May 2020 Results (n=1697) meta-analysis of meta-analysis of individual patient data from five studies (CHARTA (NCT01321957), OLIVIA (NCT00778102), STEAM (NCT01765582, only combined FOLFOXIRI/bev and FOLFOX/bev arms), TRIBE (NCT00719797) and TRIBE2 (NCT02339116)), presented at the 56th Annual Meeting of the American Society of Clinical Oncology.